Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx) Meeting Abstract

  

Authors:	Dittamore, R. V.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; Landers, M. A.; Scher, H. I.
Abstract Title:	Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx)
Meeting Title:	53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	35
Issue:	15 Suppl.
Meeting Dates:	2017 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2017-05-20
Start Page:	281s
Language:	English
ACCESSION:	WOS:000411931703065
DOI:	10.1200/JCO.2017.35.15_suppl.5076
PROVIDER:	wos
Notes:	Meeting Abstract: 5076 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/147116